FARLUTAL DEPOT 500mg Price

Overview

Welcome to Dwaey, specifically on FARLUTAL DEPOT 500mg Injection page.
This medicine contains an important and useful components, as it consists of Medroxyprogesterone acetate.
FARLUTAL DEPOT 500mg is available in the market in concentration 500mg/Vial and in the form of Injection.

FARMITALIA CARLO ERBA is the producer of FARLUTAL DEPOT 500mg and it is imported from ITALY, The most popular alternatives of FARLUTAL DEPOT 500mg are listed downward .

Mode Of Action

Medroxyprogesterone is a synthetic progestogen which converts the proliferative phase of the endometrium into secretory phase. It has some androgenic and anabolic activities but no oestrogenic effects. Parenteral use leads to inhibition of pituitary gonadotropins, thus preventing follicular maturation and ovulation.

Indication

• Menorrhagia
• endometriosis
• secondary amenorrhoea
• contraception
• abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology

Precaution

Breakthrough bleeding is likely to occur in patients being treated for endometriosis. May cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, asthma, or cardiac or renal dysfunction, require careful observation. A decrease in glucose tolerance has been observed in some patients. Patients with depression, DM, epilepsy, asthma, migraine, hypertension, renal or cardiac dysfunction. Monitor patient closely for loss of vision, proptosis, diplopia and thromboembolic disorders. Lactation: Safe

Side Effects

• >10% Amenorrhea
• Breakthrough bleeding
• Change in menstrual flow
• Spotting
• Edema
• Anorexia
• Weakness
• Pain at injection site Frequency Not Defined Angioedema
• Change in weight
• Depression
• Dizziness
• Headache
• Nervousness
• Somnolence
• Breast tenderness
• Galactorrhea
• Abdominal pain
• Nausea and vomiting
• Cholestatic jaundice
• Deep vein thrombosis (DVT)
• Thrombophlebitis Potentially Fatal: Thrombophlebitis and pulmonary embolism.

Contra indication

Thromboembolic disorders; cerebral apoplexy; severe hepatic dysfunction; incomplete abortion, hormone-dependent carcinoma; Undiagnosed vaginal bleeding, Undiagnosed urinary tract bleeding, Known or suspected pregnancy, Undiagnosed breast pathology, Missed abortion, Active thromboembolic disorders, Markedly impaired liver function,

Pregnancy and lactation

Pregnancy category: X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.